

ImmunID at the 34th CTRC-AACR San Antonio Breast Cancer Symposium

The 34th San Antonio Breast Cancer Symposium was held on December 6-10, 2011. It drew nearly **8000 participants – mainly oncologists, scientists and pharmaceutical companies executives** – from over 90 countries (sabcs.org). ImmunID participated in this major breast cancer conference, for which the main themes were emerging treatments in difficult-to-treat populations, including patients with metastatic cancer, and new knowledge about risk and prevention.

During the conference, **we presented our work on Lympho-Divpenia in metastatic breast cancer, performed in collaboration with the Centre Léon Bérard**. Our expertise in measuring immune repertoire diversity and in screening for divpenia sparked great interest.

2011 was marked by significant progress in the fight against breast cancer. Over the four days of the symposium, we particularly noted **two significant advances which could have an impact on ImmunID's activity**. The first one relates to the results of **Roche's CLEOPATRA study** ([press release](#)). This is a phase III clinical trial in HER-2 positive metastatic breast cancer patients. Roche showed that a new drug – Pertuzumab, an antibody specifically directed against the HER2 receptor – in combination with standard treatment (Trastuzumab and Docetaxel) improved Progression Free Survival (PFS) by 6.1 months compared to standard treatment (12.4 months for Trastuzumab and Docetaxel vs. 18.5 months for Pertuzumab, Trastuzumab and Docetaxel), thus contributing to patient quality of life. Overall survival (OS) data are currently immature, with a trend in favour of the Pertuzumab combination. Our attention was also attracted by comments on the **role of leukocytes in metastatic progression and therapeutic responses** made by Dr Kornelia Polyak, MD, PhD at the Dana-Farber Cancer Institute, during the SABCS closing session. Relating to preclinical work, her talk underlined the relevance of leukocytes in predicting tumor progression and treatment efficacy, particularly in models of metastatic cancer. This reinforces the potential of ImmunID's tests when performed in the clinical setting.

2011 was a year with multiple projects and successes for ImmunID. Our selection to present a poster at the San Antonio Breast Cancer Symposium was an appropriately positive culmination to the year. It also allowed the company to close the year with an emphasis on breast cancer, on which we record significant advances ([press release](#)). There is a great need for a more personalized medicine in metastatic breast cancer, and ImmunID is looking forward to continue contributing to it in 2012.

[ImmunID and the Centre Léon Bérard presented their work on Lympho-Divpenia in metastatic breast cancer at the 2011 SABCS short link](#)

[ImmunID at the 34th SABCS: great end to 2011. The company made significant advances in the field of breast cancer. short link](#)

MESH keywords: metastatic breast cancer, San Antonio Breast Cancer Symposium, SABCS 2011, Léon Bérard Cancer Centre, Lympho-Divpenia